Valuation: MacroGenics, Inc.

Market Cap 261M 225M 212M 192M 362M 24.96B 367M 2.48B 973M 12.48B 978M 957M 41.59B P/E 2026 *
-2.64x
P/E 2027 * -2.67x
Enterprise Value 261M 225M 212M 192M 362M 24.96B 367M 2.48B 973M 12.48B 978M 957M 41.59B EV / Sales 2026 *
2.27x
EV / Sales 2027 * 2.65x
Free-Float
96.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.74%
1 week+4.34%
Current month+10.84%
1 month-8.91%
3 months-5.98%
6 months+140.59%
Current year+154.04%
1 week 3.78
Extreme 3.785
4.31
1 month 3.36
Extreme 3.36
4.63
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
28.09
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 12/08/2025
Director of Finance/CFO 59 30/04/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 31/08/2001
Director/Board Member 53 12/08/2025
Director/Board Member 62 30/09/2004
Date Insider Type Main position Quantity % Market Cap.
19/05/26 Free

Director

25,750 0.0405%
19/05/26 Free

Director

25,750 0.0405%
19/05/26 Free

Founder

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%+4.34%+169.08%-17.21% 261M
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.23%+14.59%+55.99%+91.19% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
+0.67%+3.78%+39.49%-15.27% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average -0.09%+3.70%+68.06%+176.07% 28.08B
Weighted average by Cap. -0.05%+5.69%+57.09%+163.95%

Financials

2026 *2027 *
Net sales 115M 98.96M 93.11M 84.62M 159M 10.98B 161M 1.09B 428M 5.49B 430M 421M 18.29B 98.35M 84.94M 79.92M 72.64M 137M 9.42B 139M 937M 367M 4.71B 369M 361M 15.7B
Net income -88.02M -76.02M -71.53M -65.01M -122M -8.43B -124M -839M -329M -4.22B -330M -323M -14.05B -128M -110M -104M -94.26M -177M -12.23B -180M -1.22B -477M -6.12B -479M -469M -20.37B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
18/08/26 US$4.090 +0.74% 430,575
17/08/26 US$4.060 -3.79% 638,434
14/08/26 US$4.220 +3.43% 851,459
13/08/26 US$4.080 +1.49% 1,383,088
12/08/26 US$4.020 +2.55% 339,281
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.090USD
Average target price
7.250USD
Spread / Average Target
+77.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock